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HE National Acute Spinal Cord Injury Study
Group has conducted the first multi-center randomized clinical trial of a treatment modality for acute spinal cord injury. The study contrasted the efficacy of a 1-gm bolus dose of methylprednisolone sodium succinate (MPSS) followed by 1 gm daily for 10 days with results of an identical regimen using 0.1 gm of MPSS. We have previously reported the absence of any effect of the high-dose MPSS on neurological function 6 weeks and 6 months after injury. 2 This paper reports our analysis of the neurological function of these subjects 1 year after injury, and more fully explores case fatality associated with treatment.
Study Methods
The study methods have been previously reported in detail 2 and are summarized here.
Organization
The neurosurgical departments at nine hospitals in seven states participated in the study (see Appendix). A research assistant monitored daily study activities, drug administration, and follow-up examinations. Randomization of patients was arranged through a telephone manned 24 hours a day. The MPSS was provided in uniquely numbered "look-alike" packages.*
Patient Recruitment and Randomization
The first patient entered the study on February I 1, 1979, and the last on N o v e m b e r 6, 1981. Patients were eligible for randomization if diagnosed in the emergency room as having acute spinal cord trauma. Any loss of sensation (pinprick or light touch) or of motor function below the lesion was considered indicative of spinal cord trauma. Patients with root involvement and with cauda equina lesions alone were excluded. Additional reasons for exclusion from randomization were: 1) admittance more than 48 hours after injury; 2) patient had received more than 100 mg MPSS (or its equivalent) prior to admission; 3) severe co-morbidity; 4) age under 13 years; 5) failure to obtain signed consent; and 6) the decision of participating physicians, at their discretion, to exclude certain patients.
Within each hospital the drug protocols were "blocked" to assure that, for every six randomized patients, three were in each study protocol. In all, 330 patients were randomized to the steroid treatments, and these patients were evenly distributed between the two protocols within each center. Nine patients were excluded because they received excess steroid before admission, seven did not have a spinal cord injury, two were randomized without consent, and six were ineligible. The 24 patients excluded from analysis were also evenly divided between the two treatment groups.
Steroid Administration
The MPSS schedule for each patient consisted of a bolus dose and a 10-day maintenance dose. Both treatments were identical in appearance and solubility, and were administered in the same manner. Immediately following randomization, the patient received a bolus dose of 100 mg or 1000 mg, and every 6 hours thereafter for 10 days either 25 or 250 mg of MPSS, respectively. The bolus dose was administered into the patient's maintenance intravenous line over a 10-minute period. Subsequent doses were administered over 1 minute using a buretrol, either directly or through the maintenance intravenous line.
"First-order drug violations" occurred when the patient received the correct total drug dose (1100 mg or 11,000 mg) over 1~ days, but variations occurred within the regimen. "Second-order violations" were when the patient received less than the total drug regimen (1100 mg or 11,000 mg). Protocol "variations" occurred when patients did not complete their drug regimen for reasons considered legitimate in the study protocol. The number of protocol violations and variations did not differ significantly between steroid protocols.
Neurological Examination and Clinical Data
Each patient's baseline neurological state was assessed on admission to the participating center. Identical follow-up examinations were conducted 6 weeks (Days 30 to 90), 6 months (Days 170 to 240), and 1 year (Days 365 to 425) after injury. Case fatality was ascertained at any time during the year after injury.
Outcome Measurements
Three neurological parameters are utilized in the present report: motor function, response to pinprick, and light touch sensation. Each parameter is considered in terms of the patient's score 1 year after injury compared with the admission score.
Motor Function. Fourteen muscles were evaluated for: 1) normal function; 2) reduced function but active movement against resistance; 3) active movement against gravity; 4) active movement but not against gravity; 5) some trace of contraction; or 6) no contraction. Since the score of each muscle ranged from 1 (normal) to 6 (no contraction), an "expanded" motor score ranging from 14 (all muscles normal) to 84 (no contraction in any muscle) was derived bilaterally for each patient.
From these results the following five-point scale was derived. Patients were defined as: 1) "quadriplegic" if the most cephalad muscle with no contraction was the first dorsal interosseus (representing spinal segments C-8 and T-1) or higher and no distal muscles showed contraction; 2) "paraplegic" if the most cephalad muscle with no contraction was below the first dorsal interosseus and no distal muscles showed contraction; 3) "quadriparetic" if the most cephalad muscle with a trace of contraction or having active movement but not against gravity was the first dorsal interosseus or higher; 4) "paraparetic" if the most cephalad muscle with a trace of contraction or having active movement but not against gravity was below the first dorsal interosseus; and 5) "minimal function" for all other patients.
Pinprick and Light Touch
Response. The patient's response to pinprick and light touch was evaluated bilaterally for each spinal cord segment and was scored as being: 1) normal, 2) decreased, or 3) absent. The expanded score for each parameter therefore ranged from 29 (representing a normal response at each level) to 87 (absent response at all levels). The following fivepoint scale was derived from the same examination. Patients were defined as: 1) "analgesic >_ T -I " and "anesthetic _> T-1" if pinprick and light touch sensation, respectively, were absent at T-1 or above and in all distal segments; 2) "analgesic < T-1" and "anesthetic < T-1" if sensation was absent below T-1 and in all distal segments; 3) "hypalgesic _ T -l " and "hypesthetic _> T -l " if sensation was decreased at T-1 or above; 4) "hypalgesic < T-l" and "hypesthetic < T-1" if sensation was decreased below T-l; and 5) "normal" for other patients.
Completeness of Neurological Deficit. Patients were further defined as being: 1) quadriplegic with total sensory loss; 2) paraplegic with total sensory loss; 3) quadriplegic with partial sensory loss; 4) paraplegic with partial sensory loss; and 5) paretic (quadriparetic, paraparetic, or minimal function) with variable sensory loss. Most analyses group this scale into: 1) plegic patients with total sensory loss; 2) plegic patients with partial sensory loss; and 3) paretic patients with variable sensory loss.
Changes in Neurological Status. Changes in neurological status ("change score") were determined by subtracting the expanded neurological scores at admission from the l-year scores. Thus, a negative score represents improved neurological function. The patients' right side was arbitrarily selected to represent neurological status. In the present analysis the change score is treated as a continuous measure.
Multivariate Analysis of l-Year Follow-Up Scores
A multivariate analysis of the 1-year change scores was conducted by regressing the change scores on the steroid protocol (high or low) and on a large number of potentially confounding variables. These were race (white, black, or other), degree of consciousness (normal or decreased), results of plain spine x-ray films (no fracture or dislocation, either fracture or dislocation, or both fracture and dislocation), myelogram results (no block, partial block, total block, and study not performed), injury type (open or closed), presence of any protocol violation after randomization, age, sex, blood pressure, pulse rate, relative weight (weight/height), time between accident and admission, time interval from accident to 1-year examination, presence ofcauda equina lesions, immobilization of the patient, and cause of injury (vehicle or other). One of the most important potential confounders was the study center, because the types of injury, patient characteristics, and management of spinal cord injury vary among them. The second major potential confounder was neurological status at admission to the center.
The analysis relied on the method of "backward elimination. ' '7 In this procedure the partial F statistic for each variable is computed to test whether that variable significantly helps in predicting the dependent variable in the presence of other variables already in the model. All potentially important independent variables were first included in the model. Since there were some missing values for pulse, systolic and diastolic blood pressure, and time to loading dose from injury, these were checked first for non-significance and then deleted from further analysis to increase the usable sample size. This produced a baseline model from which all other independent variables were deleted one at a time, those with the highest p value being deleted first. Deletion continued until all remaining values had a p value of not more than 0.10, this being the final model. Records of the steroid protocol, the relevant emergency room neurological score, and the study center were deliberately retained in all models. For the partially plegic group, the small sample size necessitated a different approach. All-possible-subsets regression was performed using Mallow's Cp statistic as a criterion of goodness of fit for subset selection. Mallow's Cp serves as an estimate of the standardized total squared error from a fitting equation. Subset selection obtains a balance of minimal bias, low average error of prediction, and simplicity of the model. 22
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Results
Characteristics of Patients in Treatment Groups
Differences in patient characteristics between the two groups were extremely small and, where comparisons can be made, reflect the characteristics of patients with spinal cord injury as it occurs nationallyP The referral patterns of patients to the participating centers were also almost identical. 2 Overall, 256 cases (89.5%) were available for followup study at 1 year: 32 patients had died and 224 had a 1-year neurological examination. The proportion of patients examined did not differ between the high-and low-dose steroid groups (76.3% and 70.1%, respectively; X~ = 1.492). Fifty-four patients were examined beyond the study protocol time of 425 days from injury, but this proportion also did not differ between the highand low-dose treatment protocols (22.4% and 25.9%, respectively; X~ = 0.377).
Neurological Status on Admission
The neurological status of patients on admission to the study hospital was not significantly different between the two treatment groups. 2 The distribution of patients by completeness of neurological deficit did not differ between the two steroid treatment groups. For subsequent analyses, we focused on three major groups of patients: plegic patients with total sensory loss (51.0% of the total sample); plegic patients with partial sensory loss (20.6%); and paretic patients with variable sensory loss (28.4%). Figure 1 shows the unadjusted neurological scores for motor function, pinprick response, and touch sensation for the high-and low-dose MPSS treatment groups. For each modality there is a reduction in dysfunction over each of the follow-up periods which continues throughout 1 year. The slight neurological advantage of the high-dose MPSS group in the emergency room score (which was not statistically significant but was adjusted for in all multivariate analyses) is maintained at every examination period. The purpose of the present statistical analysis is to examine the 1-year neurological scores, adjusting for potentially confounding variables, including the emergency room neurological score, and to examine them for the three specific spinal cord injury groups defined on admission (that is, plegic, total sensory loss; plegic, partial sensory loss; and paretic, variable sensory loss).
Neurological Status at 1 Year
The mean l-year changes in motor function, pinprick response, and touch sensation by steroid treatment are summarized in Table 1 . Improvement in neurological function occurred in every parameter and for each level of injury. Overall, motor improvement was greatest in the partially plegic patients, followed by the paretic patients. Completely plegic patients showed least return of function. Recovery of sensation showed less variability between the three extent-of-injury groups than FIG. 1. Motor function, pinprick response, and touch sensation scores determined by neurological examination in the emergency room (ER) and at 6 weeks, 6 months, and 1 year. For scoring system see text. L = low-dose group; H = high-dose group. did m o t o r function. In n o n e of the comparisons, however, is there a significant difference in the degree of neurological i m p r o v e m e n t between the two steroid t r e a t m e n t groups.
The final results of the analyses of covariance for 1-year changes in m o t o r function, pinprick, a n d touch sensation, c o m p a r e d to initial extent of injury, are shown in Tables 2 to 4 , respectively.
M o t o r Function.
For each of the three extent-ofi n j u r y groups, the difference in the effect of the two steroid treatments on change in m o t o r function at 1 year continues to be statistically non-significant after adjusting for other factors (Table 2) showed greater m o t o r f u n c t i o n i m p r o v e m e n t (30.03 change score units, p = 0.001) t h a n males. Individuals e x a m i n e d b e y o n d the 425th day i m p r o v e d more than those e x a m i n e d on or before the 425th day (20.02 change score units, p = 0.01 18). A m o n g paretic patients with variable anesthesia, those with a closed injury showed significantly greater i m p r o v e m e n t (6.67 motor change score units, p = 0.0336) t h a n patients with open injuries, after a d j u s t m e n t for other factors.
P i n p r i c k Sensation.
There is also no effect of steroid t r e a t m e n t protocol on pinprick sensation at 1 year for a n y of the extent-of-injury categories after adjustment for other variables (Table 3) . A m o n g plegic patients with complete anesthesia, those w i t h o u t evidence of a block on their myelogram were significantly more likely to have i m p r o v e d pinprick sensation at 1 year than were those patients with a total block (an average difference of 10.82 change-score units, p = 0.0006). Patients with a partial block also showed relatively greater i m p r o v e m e n t (4.83 units, p = 0.103). A m o n g plegic patients with partial anesthesia, those with c a u d a equina lesions showed significantly greater return of pinprick sensation (12.05 change score units, p = 0.0037). Patients with decreased consciousness on admission also showed relatively greater i m p r o v e m e n t (10.06 units, * Initial extent of injury as diagnosed on admission to the emergency room (ER) of the treating center. p = 0.0151) t h a n patients with n o r m a l consciousness, after a d j u s t m e n t for other factors. Partially plegic patients e x a m i n e d b e y o n d Day 425 also showed significantly greater i m p r o v e m e n t over those e x a m i n e d earlier (18.64 units, p = 0.0001). For paretic patients the most i m p o r t a n t predictor of i m p r o v e m e n t in pinprick sensation at 1 year was a higher level of pinprick dysfunction on a d m i s s i o n ( -0 . 4 4 change units for each point in the initial pinprick score, p = 0.0001).
Touch S e n s a t i o n .
The effect of steroid t r e a t m e n t on touch sensation at 1 year was not significant in plegic patients with complete anesthesia or in paretic patients (Table 4) . A m o n g plegic patients with partial anesthesia, however, those in the high-dose steroid protocol were significantly m o r e likely to show i m p r o v e m e n t in touch sensation 1 year after i n j u r y (6.12 change score units, p = 0.0057). Because steroid t r e a t m e n t is the major study variable, it was "forced" into all of the multivariable models. Thus, we m u s t be alert to the possibility of finding a significant result merely because we have conducted m u l t i p l e analyses with this variable. A Bonferoni-adjusted p value for the steroid effect is 0.06; thus, the MPSS effect is not statistically significant after a d j u s t m e n t for multiple comparisons.
A m o n g completely plegic patients, those with no block on their m y e l o g r a m showed significantly im- 
Analysis of Covariance on 1-Year Change Scores: Second Approach
In order to check further the results reported above, additional regression analyses were conducted. W h e n m o t o r function change was e x a m i n e d , the patients were first classified in the emergency r o o m as plegic or paretic. F o r each class o f patients a series of backwardstepping regression equations was run which estimated the effect of M P S S t r e a t m e n t after adjusting for potential c o n f o u n d i n g variables in the m a n n e r described earlier. Similarly, when changes in pinprick sensation were analyzed, the patients were first d i c h o t o m i z e d in the emergency r o o m as being analgesic or hypalgesic. W h e n considering changes in touch sensation we first classified the patients as being anesthetic or hypesthetic. The results o f those analyses essentially replicated those using the c o m b i n e d extent-of-injury levels described above, with one i m p o r t a n t exception: none o f the touch change scores were significantly different between the steroid protocols. A m o n g the anesthetic group, the adjusted difference in the touch change score was 0,35 (p = 0.8605) and in the hypesthetic group it was 1.09 (p = 0.4619). N o n e o f the other MPSS p r o t o c o l effects a p p r o a c h e d statistical significance, thus replicating the first analysis.
Total Steroid Dose Analysis
In a d d i t i o n to the steroids given in the study protocol, other steroids were a d m i n i s t e r e d to some patients before admission to the study center. This occurred in 38.6% and 30.3% o f patients in the high-and low-dose steroid protocols, respectively (p = 0.15). A very few patients received s o m e steroids after the M P S S protocol was terminated. O t h e r patients were inadvertently not given their full t r e a t m e n t of MPSS ( 13.2% a n d 9.1% o f patients in the high-and low-dose steroid protocols, respectively, p = 0.51). A total steroid dose was calculated for all patients in the study. Steroids other than MPSS were c o n v e r t e d into M P S S milligram equivalents. An analysis o f covariance was p e r f o r m e d as described above, but with the inclusion of total steroid dose: a total dose a n d protocol group interaction term was applied to test if the effect o f total steroid dose varied between the two protocols, and a q u a d r a t i c term was applied for total dose to test for any hyperbolic effects of total dose on the change score.
The m e a n M P S S dose for patients in the high-dose protocol was 10,668.6 mg ( m e d i a n 11,00 mg), and 1109.6 mg ( m e d i a n 1 100 mg) for those in the low-dose protocol. The analysis o f covariance found no effect o f total steroid dose on neurological recovery (p = 0.568). Neither the interaction nor quadratic terms were significant.
Relative Weight Analysis
To look for the influence of patient b o d y mass on any possible steroid t r e a t m e n t effects, we c o m p a r e d m e a n changes in the 1-year neurological status ( m o t o r function, p i n p r i c k response, and touch sensation) between the two steroid protocols within the patients' relative weight tertile ( < 2.16, 2.16 to 2.5, a n d > 2.5). N o n e o f the t r e a t m e n t effects were significantly different within each tertile (a result replicating the earlier failure o f relative weight to enter any o f the m u l t i v a r i a t e models). patients surviving according to MPSS treatment group, based on a probability density function, is presented in Fig. 2 left. Both treatment groups showed a higher case fatality rate in the period immediately after injury. There is no overall difference in case fatality between the MPSS groups (generalized Wilcoxon (Breslow) test = 1.33, p = 0.25). The risk of death within the first 2 weeks was greater for patients treated with high-dose MPSS (relative risk = 3.1, 95% CI 0.85, 11.26), although this difference was not statistically significant. The risk of death declined after 2 weeks. A hazard function was computed which indicated that the greatest risk of death for patients in the high-dose MPSS group (3.5 % risk) occurred between Days 10 to 15, then declined. No deaths occurred after 210 days. In the lowdose MPSS group, the greatest probability of death (2.1%) occurred between Days 20 and 25. There were no deaths after Day 55 in the low-dose MPSS group. Cox's proportional hazards linear modeling was used to adjust for emergency room motor function score. Patients in the high-dose MPSS group had an adjusted increased risk of death of 57.5% (standard error of the mean = 36.2, p = 0.112). Average time to death did not differ between the high-and low-dose treatment groups (37.6 and 26.9 days, respectively, p --0.44).
Case Fatality Rates
Patients with severe motor dysfunction in the high-dose steroid protocol were also no more likely to die than were severely injured patients in the low-dose schedule (X 2 = 1.78, p = 0.183). Although none of the case fatality analyses showed statistically significant differences between the two steroid protocols, we conducted a detailed case review of all the deaths in the study. However, none of the deaths could be linked to steroid treatment.
Case fatality was not associated with patients' sex but was strongly associated with extent of injury, as shown in Table 5 and Fig. 2 right. Among completely quadriplegic patients, 26 died (17.4 expected), compared with four partially plegic patients (5.1 expected) and two paretic patients (9.5 expected, p = 0.0005). The greatest risk of death in cases of complete quadriplegia occurred between Days l0 and 15 (3.7% risk), followed by Days 20 to 25 (2.6%) and Days 0 to 5 (2.4%). There were too few deaths in the other injury groups to examine their risk of death for each interval.
Case fatality in older patients was significantly elevated (3.7%, 7.9%, and 38.6% for ages < 25, 25 to 49, and > 49 years, respectively, p = 0.000 I). No significant interaction was found, however, between steroid treatment, age, and case fatality, after adjustment for initial severity of injury (X 2 = 2.8 l, p -0.243).
Discussion
This multi-center randomized clinical trial has revealed that acute spinal cord injury patients treated with a 1.0-gm daily dose of MPSS have rates of neurological recovery 1 year after injury almost identical to those of patients treated with a 0.1-gm standard dose. The 1-year findings are in accord with those reported previously for recovery at 6 weeks and 6 months after injury. 2 The majority of animal studies report improved function after steroid t r e a t m e n t , 1"4-6"8-11'14"17-19"21 with only three studies not showing a beneficial effect. 15' 16' 25 White-matter sparing occurred with steroid treatment in one study, although functional status was unchanged. 9 However, the widespread clinical use of steroids has never been shown to be efficacious. 23 '24 What may account for our discrepant animal and human experience with steroids? Physiological, biochemical, and anatomical differences, and variation in the biological response to trauma may all be factors. 2~ It may also be difficult to extrapolate from results of the weight-dropping technique used for causing injury in experimental animals to human injuries that often include a rotation factor, which is the principal source of injury to the spinal cord following fracture dislocations. 12.25 It is also possible that the high MPSS dose used in this study did not reach therapeutic levels. The average 73.4-kg patient in our study would have received 13.6 mg/kg daily in the high-dose treatment. However, patient weights ranged from 45.4 to 127.1 kg, providing high-dose steroid treatment of 22.0 to 7.9 mg/kg. Nonetheless, the relative weight analyses reported in this paper indicate that, even among the lighter and, therefore, more heavily medicated patients, no treatment effects were observed. Future studies should include a method for reducing variability in the dose of drug given to patients of different body masses. It has recently been suggested that MPSS doses of 15 to 30 mg/kg body weight are necessary to improve neuronal excitability and impulse conduction, increase postinjury blood flow, and preserve cord ultrastructure by reducing injury-induced, free radical-catalyzed lipid peroxidation. 13 Theoretically, one would expect MPSS to be most efficacious, if it is efficacious at all, when given soon after injury. Only 36 patients (12.0%) started MPSS treatment within 3 hours after trauma, and 62 started within 3 to 6 hours of their injury. Although analyses of these subgroups failed to find any MPSS effects, small MPSS effects could be missed because so few patients were involved.
In this study, we were not able to compare the highdose steroid against placebo. At the time the study was established, existing widespread use of steroids and concern over potential medical malpractice suits if steroids were withheld dampened enthusiasm for a placebo study arm. Any interpretation of the lack of a treatment effect observed by us, therefore, must include the theoretical possibility that both doses of steroid were of equal benefit. Our failure to find any evidence of a steroid dose-response relationship in the many analyses carried out on these data sets make such a conclusion unlikely. Nonetheless, this explanation can only be completely ruled out by including a placebo arm in future studies of MPSS and other pharmacological agents.
We did observe a modest improvement in touch sensation at 1 year among partially plegic patients treated with high-dose steroids (p = 0.06 after correction for multiple observations). Unfortunately, this result was not replicated among paretic patients where it might have been expected if the effect was real, nor was it found in any of the other statistical analyses. Moreover, the 6-week and 6-month analyses 2 also did not support this finding. We must conclude, therefore, that this is a chance observation in this data set although it merits further investigation in new studies.
The present study confirms the importance of a complete block on myelography as an indicator on admission after injury that improvement in function is unlikely. In our data this was particularly true among patients with complete loss of both motor and sensory function with respect to predicting poor return of pinprick and touch sensation. Even after adjustment for severity of injury, older completely plegic patients showed significantly improved return of motor function compared to younger patients with the same deficit. In this clinical series, however, only one-fifth of the patients were over age 40 years; older age, therefore, generally refers to patients who are 30 to 50 years of age. Partially plegic patients show greater return of motor function if they are female and more return of touch if male. The possible reasons for this are not known. It is notable that the patient, injury, diagnostic, and treatment factors studied by us were successful in explaining a large a m o u n t of the variability in neurological recovery (shown by the R 2 statistic in Tables 2  to 4 ). This was particularly true for sensory recovery in partially plegic and paretic patients and somewhat less so for completely plegic patients. Our least predictive model, motor function in completely plegic patients, still explained 18% of the variance in 1-year motor change scores. Other patient and treatment factors, not studied by us, must account for the variability not explained in the statistical models.
We noted that partially plegic patients examined after
Day 425 showed significantly greater improvement in motor and pinprick function. This may reflect further improvement in these patients with the passage of time, in which case it is an observation of great interest. However, the more functional patients may have been disproportionately less likely than the less functional patients to be examined at the l-year follow-up period because some had lost contact with their treating hospital. Only sequential analyses of the same patients beyond 1 year can evaluate whether partially plegic patients actually do continue to improve beyond the 1 st year after injury.
It is important to note that the proportion of patients lost to follow-up review and those examined beyond Day 425 did not differ between the two treatment arms of the study. Late examination time was also adjusted in the statistical models to further correct for any possible bias from this source. Thus, differential loss to follow-up review or length of follow-up period could not have biased the neurological results of the study as they relate to MPSS treatment.
The case fatality rate was 10.7% within 1 year of injury, a figure that is very similar to the 11.2% rate reported in national data 3 for deaths occurring during initial hospitalization. The present data indicate that the probability of death after hospital discharge but within the 1st year after injury is very low. Risk of death was not associated with steroid protocol or patient gender, but there were significantly more deaths in the year following injury a m o n g completely plegic patients (p = 0.0005) and among patients 50 years of age or older (p = 0.0001).
